Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by varying degrees of inflammation and fibrosis of the lung interstitium. This article provides a comprehensive overview of ILDs, focusing on their classification, clinical manifestations, diagnostic strategies, and treatment options.
ILDs can be classified based on the underlying etiology into three main categories: idiopathic, secondary to systemic diseases, and those associated with exposure to certain environmental or occupational agents. The most common form of ILD is idiopathic pulmonary fibrosis, a progressive fibrotic disorder of unknown cause.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Physical examination may reveal inspiratory crackles and finger clubbing. Pulmonary function tests often show a restrictive pattern with reduced diffusing capacity for carbon monoxide.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs. It can reveal characteristic patterns such as reticulation, honeycombing, and ground-glass opacities. Lung biopsy, either surgical or via bronchoscopy, is often required for definitive diagnosis, particularly for idiopathic forms.
Management of ILDs involves addressing the underlying cause, if identifiable, and providing supportive care. Pharmacological treatment includes corticosteroids and immunosuppressive agents. Antifibrotic drugs such as pirfenidone and nintedanib have shown promise in slowing disease progression in idiopathic pulmonary fibrosis. Lung transplantation may be considered in advanced cases.
Interstitial lung diseases represent a complex group of pulmonary disorders with diverse etiologies and clinical manifestations. A thorough understanding of these conditions is essential for prompt diagnosis and effective management. Further research is needed to elucidate the pathogenesis of these diseases and develop novel therapeutic strategies.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation